Impact of a targeted hepatitis B vaccination program in Amsterdam, The Netherlands.
To evaluate hepatitis B virus (HBV) risk group vaccination in Amsterdam, which started in 1998, we examined 342 reported acute HBV-cases and sequenced 85 DNA isolates. The reported number of cases declined from 214 in 1992-1997 to 128 in 1998-2003, due to a decline in injecting drug users (IDU) and their heterosexual partners. Phylogenetic analyses showed that after 1998, the IDU cluster nearly disappeared, probably due to a decline in injecting. Acute HBV remained stable among men having sex with men; given their increased sexual risk behavior, vaccination has probably prevented an increase in their acute infections. Currently, 48-72% of the people who should be included in the program are still susceptible to HBV.
van Houdt
Robin
R
GGD, Public Health Service, Department of Infectious Diseases, Amsterdam, The Netherlands. rvhoudt@ggd.amsterdam.nl
Sonder
Gerard J B
GJ
Dukers
Nicole H T M
NH
Bovee
Lian P M J
LP
van den Hoek
Anneke
A
Coutinho
Roel A
RA
Bruisten
Sylvia M
SM
D005260:Female; D005838:Genotype; D006509:Hepatitis B / Q000453:epidemiology / Q000209:etiology; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006515:Hepatitis B virus / Q000145:classification / Q000235:genetics; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D009426:Netherlands / Q000453:epidemiology; D010802:Phylogeny; D012189:Retrospective Studies; D015819:Substance Abuse, Intravenous / Q000150:complications; D014611:Vaccination
D017325:Hepatitis B Vaccines